At a glance
Bruker Corporation is worth $9.41B. Revenue grew 2.1% to $3.44B in fiscal 2025, at a loss; over 5 years it has grown 11.6% a year. It pays a 0.32% dividend yield, and returned $715.1M to shareholders in dividends and buybacks over FY2021–FY2025. The stock returned +60.8% over the past year with dividends reinvested and −4.6% a year over five years, against +11.5% and +11.7% for the S&P 500. At its worst it fell 36.2% in the 2020 crash (S&P 500: 33.7%) and 39.5% in the 2022 bear market (S&P 500: 24.5%), and was back at its earlier high 8 months and 7 months after the lows.
The business in plain English
Bruker designs, makes and sells high-end scientific instruments that let researchers study materials, molecules and cells at microscopic scale. Its tools rely on technologies such as nuclear magnetic resonance (NMR, which uses powerful magnets to reveal a molecule's structure), mass spectrometry (which identifies molecules by measuring their mass), X-ray, microscopy and chromatography. Customers include university and government labs, drug and biotech companies, food, chemical and industrial firms, and clinical microbiology labs. The company is based in Billerica, Massachusetts, with major manufacturing centers in Europe and North America.
Revenue was $3.44 billion in fiscal 2025, which ended December 31, 2025, split across four segments. BSI CALID, the largest at 35.2%, sells mass spectrometers plus microbiology and infectious-disease testing products. BSI NANO contributed 31.6%. BSI BioSpin, at 25.6%, sells NMR systems and preclinical imaging scanners for animal research; most of its customers are academic and government labs. Bruker Energy & Supercon Technologies made up the remaining 7.7%.
Most money comes from selling instruments: products were 80.5% of revenue, with services and other sales making up 19.5%. Bruker also offers servicing, software and lab automation, and aims to grow recurring revenue from support after the sale. Sales are global. Europe outside Germany accounted for 27.7%, the US 25.9%, Asia Pacific outside China 16.1%, China 13.8% and Germany 8.6%.
Price history
The interactive chart needs JavaScript.
BRKR +60.8% over the year to Oct 28, 2026, total return with dividends reinvested.
How it makes money
By product or service
| Product | $2.77B | 80.5% |
| Product And Service Other | $670.1M | 19.5% |
By business segment
| Bsi Calid | $1.21B | 35.2% |
| Bsi Nano | $1.08B | 31.6% |
| Bsi Biospin | $878.8M | 25.6% |
| Energy And Supercon Technologies | $263.2M | 7.7% |
By geography
| Europe Excluding Germany | $950.2M | 27.7% |
| US | $891.3M | 25.9% |
| Asia Pacific Excluding China | $552.6M | 16.1% |
| CN | $475.8M | 13.8% |
| DE | $297.0M | 8.6% |
| Other Country | $269.6M | 7.8% |
Latest results
- In Q2 FY2026 (ended Jun 30, 2026), revenue was $838.5M, up 5.2% from a year earlier, and net income was $-52.0M (-784.2%).
- For fiscal 2025, revenue was $3.44B (+2.1% year over year; +11.6% a year from FY2020 to FY2025) with a -0.3% net margin.
Financial health check
| Revenue growth a year (FY2020–FY2025) | +11.6% good |
|---|---|
| Operating margin | 2% weak |
| Free cash flow margin | 1.3% watch |
| Return on equity (FY2025) | -0.4% weak |
| Return on assets (FY2025) | -0.1% weak |
| Net cash (cash minus debt) | $-1.64B weak |
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2020 | $1.99B | $157.8M | $235.0M |
| FY2021 | $2.42B | $277.1M | $190.4M |
| FY2022 | $2.53B | $296.6M | $145.2M |
| FY2023 | $2.96B | $427.2M | $243.2M |
| FY2024 | $3.37B | $113.1M | $136.0M |
| FY2025 | $3.44B | $-8.6M | $43.3M |
Valuation snapshot
| Market value | $9.41B |
|---|---|
| P/E ratio | — |
| Dividend yield | 0.32% |
Rank among 1514 US companies
Market value at each year end
Bruker’s market value went from $3.40B at the end of 2016 to $9.41B on Oct 28, 2026, about 2.8 times as much; since the end of 2025 it is up 32%.
Show as a table
| Year end | Market value | Change |
|---|---|---|
| Oct 28, 2026 | $9.41B | +31.6% |
| 2025 | $7.15B | -19.6% |
| 2024 | $8.89B | -12.6% |
| 2023 | $10.17B | +1.2% |
| 2022 | $10.05B | -21.0% |
| 2021 | $12.73B | +53.5% |
| 2020 | $8.29B | +5.6% |
| 2019 | $7.85B | +68.4% |
| 2018 | $4.66B | -12.7% |
| 2017 | $5.34B | +57.1% |
| 2016 | $3.40B |
Price behavior
| YTD | 1 yr | 3 yr | 5 yr | 10 yr | |
|---|---|---|---|---|---|
| BRKR price data to Oct 28, 2026 | +32.0% | +60.8% | +3.0% | -4.6% | +12.4% |
Show as a table
| Year | Price data |
|---|---|
| 2026 (to date) | +32.0% |
| 2025 | -19.2% |
| 2024 | -20.0% |
| 2023 | +7.8% |
| 2022 | -18.3% |
| 2021 | +55.4% |
| 2020 | +6.6% |
| 2019 | +71.8% |
| 2018 | -12.8% |
| 2017 | +63.0% |
| 2016 | -12.2% |
| 2015 | +23.7% |
| 2014 | -0.8% |
| 2013 | +29.7% |
| 2012 | +22.7% |
| 2011 | -25.2% |
| 2010 | +37.6% |
| 2009 | +198.5% |
| 2008 | -69.6% |
| 2007 | +77.1% |
| 2006 | +54.5% |
| 2008 financial crisis stocks fell Oct 9, 2007 – Mar 9, 2009 | Lost 53.3% over that stretch · deepest drop along the way 80.2%, back to its old high 22.9 months after the low |
|---|---|
| 2020 COVID crash stocks fell Feb 19, 2020 – Mar 23, 2020 | Lost 36.2% over that stretch · deepest drop along the way 36.2%, back to its old high 7.9 months after the low |
| 2022 bear market stocks fell Jan 3, 2022 – Oct 12, 2022 | Lost 32.6% over that stretch · deepest drop along the way 39.5%, back to its old high 6.5 months after the low |
Insider activity
Form 4 filings from 2025-10-30 to 2026-10-30 (25 read): 0 open-market purchases and 8 sales ($887K), 7 of them under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 17, 2026 | Wolfgang Pusch President BMID Group | sell | $198K |
| Jul 15, 2026 | Mark Munch EXEC VP&PRES BRUKER NANO INC. | sell (plan) | $121K |
| Aug 14, 2026 | Mark Munch EXEC VP&PRES BRUKER NANO INC. | sell (plan) | $115K |
| Jun 15, 2026 | Mark Munch EXEC VP&PRES BRUKER NANO INC. | sell (plan) | $110K |
| Sep 15, 2026 | Mark Munch EXEC VP&PRES BRUKER NANO INC. | sell (plan) | $106K |
Who owns it
Large shareholders (13G filings)
| FMR LLC | 15% | Jun 30, 2026 |
| ORBIS INVESTMENT MANAGEMENT LTD | 11.1% | Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 3% | Dec 31, 2025 |
ETFs with the most weight in BRKR
| TINY ProShares Nanotechnology ETF | 4.13% |
| KOMP SPDR S&P Kensho New Economies Composite ETF | 0.69% |
| QMID WisdomTree U.S. MidCap Quality Growth Fund | 0.61% |
| QQQS Invesco NASDAQ Future Gen 200 ETF | 0.53% |
| FXH First Trust Health Care AlphaDEX Fund | 0.44% |
| ETHO Amplify Etho Climate Leadership U.S. ETF | 0.32% |
| FFLG Fidelity Fundamental Large Cap Growth ETF | 0.24% |
| IVOV Vanguard S&P Mid-Cap 400 Value ETF | 0.2% |
What could go wrong
- Cuts to US research funding. A meaningful share of sales goes to US universities and labs that rely partly on federal grants, such as from the National Institutes of Health. Bruker says funding cuts and delays have significantly hurt results.
- Delayed Chinese government stimulus spending. China supplied 13.8% of fiscal 2025 revenue. Bruker says delays in releasing Chinese government stimulus spending have materially hurt its results and may continue to for the foreseeable future.
- Tariffs have already hurt results. New US tariffs and retaliatory tariffs abroad have had a material negative effect on results, Bruker says, and may keep doing so. The rules remain uncertain, including after a US Supreme Court decision.
- Large debt, mostly in foreign currencies. Total debt was $1.82 billion against $185 million of cash and investments as of June 30, 2026. Most of it is in foreign currencies, so exchange-rate swings can raise or lower the dollar cost.
- Preferred shares rank ahead of common stock. Series A mandatory convertible preferred shares, which must turn into common stock by a set date, get paid ahead of common shareholders for dividends and in a liquidation. They may weigh on the share price.
- Supply chain strains add costs. Rising demand for certain components and production delays have already caused significant extra costs and manufacturing inefficiencies. Bruker relies on a limited number of suppliers and contract manufacturers.
Recent events
- Other company announcement
- Other company announcement
- Quarterly results released
- Other company announcement
- Shareholder vote results
- Other company announcement
- Quarterly results released
- Other company announcement
- Executive or board change
- Executive or board change; Other company announcement
For income and retirement investors
Bruker pays a dividend, but it is small and has not grown over five years. Dividends per share were about $0.15 in fiscal 2025, down from $0.20 in 2023 and 2024. The yield (yearly dividends divided by share price) was 0.32% as of October 28, 2026, so the stock provides little income. A net loss in fiscal 2025 meant earnings did not cover the payout; dividends took 52.7% of free cash flow, the cash left after running the business and paying for equipment. Buybacks totaled $578.7 million from fiscal 2021 to 2025, but just $10 million in 2025 and none in 2024.
The stock has fallen sharply in past downturns. It lost 80.2% in the 2008 financial crisis and took about 23 months to recover. It dropped 36.2% in the 2020 COVID crash and 39.5% in the 2022 bear market, recovering in about 8 and 6.5 months. A single stock carries more risk than a diversified fund.
Questions investors ask
How does Bruker make money?
Mostly by selling high-end scientific instruments. Products made up 80.5% of Bruker's $3.44 billion in fiscal 2025 revenue, and services and other sales made up 19.5%. Its tools include mass spectrometers, which identify molecules by measuring their mass, NMR systems that use powerful magnets to map molecular structure, preclinical imaging scanners and microbiology testing systems. Customers include university and government labs, drug and biotech companies, food and industrial firms, and clinical labs.
Does Bruker raise its dividend every year?
No. Bruker pays a dividend but has no streak of yearly increases. Dividends per share were $0.16 in fiscal 2020 through 2022, $0.20 in 2023 and 2024, and about $0.15 in 2025, a decline of about 1.3% a year over five years. The yield was 0.32% as of October 28, 2026. Bruker's annual report warns that dividends on its common stock could be reduced or eliminated.
Is Bruker profitable?
No, based on fiscal 2025 and the quarter ended June 30, 2026. Bruker posted a net loss of $8.6 million in fiscal 2025 on revenue of $3.44 billion, down from net income of $427.2 million in fiscal 2023 and $113.1 million in 2024. Its operating margin, profit from core operations as a share of sales, was 2%. In the June 2026 quarter, revenue rose 5.2% from a year earlier to $838.5 million, but Bruker lost $52 million.
How much debt does Bruker have?
About $1.82 billion as of June 30, 2026, against $184.9 million in cash and investments, leaving net debt of about $1.64 billion. Shareholders' equity was $2.40 billion. Most of the debt is in foreign currencies, so exchange-rate moves change its dollar value. Free cash flow was just $43.3 million in fiscal 2025, and Bruker's annual report warns that its debt may restrict investment opportunities or limit its activities.
How has Bruker stock performed?
Unevenly. As of October 28, 2026, the share price was up 60.8% over one year and 32% from the start of 2026 to that date, after falling about 20% in both 2024 and 2025. Over five years it lost 4.6% a year, or 21% in total, while over 10 years it gained 12.4% a year, or 221% in total. The swings are large: its biggest peak-to-trough drop in the three years to that date was 68.7%.